Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of canakinumab in the cryopyrin-associated periodic syndrome.

The New England journal of medicine - 4 Jun 2009

Lachmann Helen J, Kone-Paut Isabelle, Kuemmerle-Deschner Jasmin B, Leslie Kieron S, Hachulla Eric, Quartier Pierre, Gitton Xavier, Widmer Albert, Patel Neha, Hawkins Philip N

Abstract excerpt

BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Double-Blind Method

Share to Familial Mediterranean Fever

Share to Interleukin-1beta

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to Young Adult

Source

Identifiers

PMID: 19494217
DOI: 10.1056/NEJMoa0810787

Genes

CAPS
CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of canakinumab in the cryopyrin-associated periodic syndrome.PMID 19494217Read ↗

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.Semantic proximity Read ↗

Canakinumab for the treatment of cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.Semantic proximity Read ↗

Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.Semantic proximity Read ↗

Pharmacological treatment options for cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

Guidelines for the management and treatment of periodic fever syndromes: Cryopyrin-associated periodic syndromes (cryopyrinopathies - CAPS).Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: background and therapeuticsSemantic proximity Read ↗

Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response.Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: diagnosis and management.Semantic proximity Read ↗

[CAPS: cryopyrin-associated periodic syndrome].Semantic proximity Read ↗

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case reportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.